Medpace 10-Q: Q3 EPS $4.84, All Book-to-Bill Suits Dismissed, New $1.0B Buyback
MEDP sits 75% above its 52-week low of $373 on elevated volume (3.2× avg).
Summary
Medpace's Q3 10-Q confirms $716.0 million of revenue and $4.84 diluted EPS, and discloses that all three book-to-bill securities suits were voluntarily dismissed in October alongside a new $1.0 billion buyback authorization.
Key Events · Earnings and Guidance · MEDP
-
Q3 Revenue Up 8.5%, EPS $4.84
Revenue rose to $716.0 million from $659.9 million and net income to $137.5 million from $111.1 million, lifting diluted EPS to $4.84 from $3.86.
-
All Book-to-Bill Suits Dismissed
The Durbin class action was voluntarily dismissed without prejudice on October 12, 2026, and the Bushansky and Mary derivative actions on October 20, 2026.
-
New $1.0 Billion Buyback Approved
Effective October 20, 2026 the board terminated the prior authorization, which had $527.0 million remaining, and approved a new repurchase authorization of up to $1.0 billion.
-
Backlog Growth Slows to 5.6%
Backlog reached $3,167.2 million versus $3,000.6 million a year earlier, with $1,980.0-$2,000.0 million expected to convert to revenue over the next twelve months.
Analysis · MEDP · Industrial Applications And Services
Two facts in this 10-Q were not in the October 21 8-K, and both matter. First, all three securities cases tied to the book-to-bill disclosures are gone: the Durbin class action was voluntarily dismissed on October 12 and both derivative suits on October 20, all without prejudice. That clears the overhang the stock has carried since the allegations surfaced. Second, the board terminated the old repurchase authorization and replaced it with up to $1.0 billion effective October 20, roughly double the $527.0 million that remained. The operating picture, by contrast, is steady rather than accelerating: revenue rose 8.5% to $716.0 million and net income 23.7% to $137.5 million, but nine-month revenue growth of 16.9% shows the third quarter decelerated, and backlog of $3,167.2 million grew only 5.6% year over year. Note the dismissals are without prejudice, so refiling is possible.
How filings like this one have moved
In the 30 days to Oct 23, 2026, 29.6% of the 1590 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.25%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MEDP was trading at $653.96 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $18.3B. The 52-week trading range was $373.00 to $684.52. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.